Program
rosuvastatin
Also written as “Rosuvastatin”, “CKD-828, D097, D337” and “Rosuvastatin 20mg”.
Its studies are mostly in Hypercholesterolemia · Hypertension · Dyslipidemias · Hyperlipidemias · Coronary Artery Disease, led by 27 companies.
Drug pageRosuvastatin: every studyMany companies study it; this page follows only the 138 they lead. All 405 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 705 open or running | phase 4since Oct 7, 2005 | Sep 16, 2005 | Jan 25, 2027phase 1 · NCT07534592 |
| Yuhanits history only | 100 open or running | phase 4since Jul 12, 2017 | Jan 5, 2012 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 80 open or running | phase 2since Nov 27, 2016 | Jan 24, 2014 | none ahead |
| Organonits history only | 60 open or running | phase 4since Mar 31, 2008 | Aug 25, 2004 | none ahead |
| GlaxoSmithKlineits history only | 40 open or running | phase 1since Dec 18, 2008 | Dec 18, 2008 | none ahead |
| Merckits history only | 40 open or running | phase 3since Oct 10, 2025 | Jun 17, 2015 | none ahead |
| Hanlim Pharm.its history only | 30 open or running | phase 3since Jun 17, 2018 | Jun 17, 2018 | none ahead |
| IlDong Pharmaceuticalits history only | 30 open or running | phase 3since Mar 5, 2014 | Mar 5, 2014 | none ahead |
| Jeil Pharmaceuticalits history only | 30 open or running | phase 3since Jun 23, 2016 | Jul 4, 2014 | none ahead |
| Lotus Pharmaceuticalits history only | 30 open or running | phase 3since May 13, 2015 | Mar 4, 2014 | none ahead |
| Celltrionits history only | 20 open or running | phase 3since Apr 27, 2026 | Jul 30, 2021 | none ahead |
| Daewon Pharmaceuticalits history only | 20 open or running | phase 3since Oct 12, 2016 | Oct 12, 2016 | none ahead |
| Daewoong Pharmaceuticalits history only | 20 open or running | phase 3since Nov 7, 2019 | Mar 14, 2014 | none ahead |
| Daiichi Sankyoits history only | 20 open or running | phase 1since Sep 11, 2025 | Sep 11, 2025 | none ahead |
| Hanmi Pharmaceuticalits history only | 20 open or running | phase 1since Mar 9, 2014 | Mar 9, 2014 | none ahead |
| kobe-universityits history only | 20 open or running | phase 4since Jun 15, 2017 | Jun 15, 2017 | none ahead |
| LG Chemits history only | 20 open or running | phase 3since Aug 5, 2013 | Aug 5, 2013 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 10 open or running | phase 3since Aug 18, 2011 | Aug 18, 2011 | none ahead |
| d16-pharma-biotec-ltd | 10 open or running | phase 4since Jun 4, 2012 | Jun 4, 2012 | none ahead |
| Dong-A STits history only | 10 open or running | phase 4since Oct 29, 2014 | Oct 29, 2014 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 11 open or running | phase 1since May 23, 2025 | May 23, 2025 | none ahead |
| HK inno.Nits history only | 10 open or running | phase 4since Nov 20, 2018 | Nov 20, 2018 | none ahead |
| hyundai-pharmits history only | 11 open or running | phase 3since Oct 15, 2024 | Oct 15, 2024 | none ahead |
| Jiangsu HengRui Medicineits history only | 10 open or running | phase 1since May 27, 2020 | May 27, 2020 | none ahead |
| NVP Healthcareits history only | 10 open or running | phase 1since Nov 9, 2014 | Nov 9, 2014 | none ahead |
| pin-siang-medical-biotechnology-co-ltdits history only | 10 open or running | no phasesince Nov 6, 2013 | Nov 6, 2013 | none ahead |
| verisfield-uk-ltd-greek-branchits history only | 10 open or running | phase 1since May 9, 2016 | May 9, 2016 | none ahead |
Also a collaborator on its studies: Parexel, Pharma Medica Research, Pfizer, Regeneron Pharmaceuticals, Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene, Eli Lilly, Linical Korea and Shionogi.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of d16-pharma-biotec-ltd only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 4, 2012First study: phase 4 study in DyslipidemiasFirst studyNCT01613729 · 2,000 enrolled · Bangladesh
TargetBeta
“HMG-CoA reductase inhibitor”ChEMBL 37, by rule
Other programs on HMGCR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Atorvastatinrule | Viatris | phase 4 | 186 |
| Simvastatinrule | Organon | phase 4 | 100 |
| pitavastatinrule | Kowa | phase 4 | 36 |
Studies
The one study d16-pharma-biotec-ltd leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01613729Dyslipidemias · Bangladesh | 4 | UNKNOWN | Jul 2013 | 2,000 |
How it is read
Names in the registry
- “Rosuvastatin”, 105 entries
- “rosuvastatin”, 10 entries
- “CKD-828, D097, D337”, 6 entries
- “Rosuvastatin 20mg”, 6 entries
- “Ezetimibe/Rosuvastatin”, 4 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 43 studies
- Hypertension, 23 studies
- Dyslipidemias, 9 studies
- Hyperlipidemias, 6 studies
- Coronary Artery Disease, 6 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.